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Hepatocellular carcinoma (HCC) causes death in patients with
cirrhosis and is one of the most prevalent malignant tumours
worldwide (Simonetti et al, 1991; Okuda, 1992; Di Bisceglie,
1995). Its incidence has substantially increased in Japan (Okuda 
et al, 1987) and in the United States (El-Serag and Mason, 1999).
HCC has a dismal 5-year survival rate, and there is no effective
chemotherapy. 
Signal transduction inhibitors, including farnesyl transferase
inhibitors and mitogen-activated protein kinase (MAPK)
kinase inhibitors, have been developed as anti-cancer agents
(Gibbs et al, 1993; James et al, 1993; Kohl et al, 1993; Stebolt-
Leopold et al, 1999). The activity of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of
cholesterol biosynthesis, has been positively correlated with
mammalian cell growth (Kandutsch and Chen, 1979). Mevalonic
acid, produced by HMG-CoA reductase, regulates cell growth
independent of cholesterogenesis: Ras p21 and lamins A and B
undergo covalent modification at the carboxyl terminus by meval-
onate-derived farnesyl isoprenoid (Goldstein and Brown, 1990).
HMG-CoA reductase inhibitors exhibit cytostatic activity possibly
as signal transduction inhibitors, when added to proliferating cells
in culture or in vivo (Goldstein et al, 1979; Habenicht et al, 1980;
Maltese et al, 1985). Decreased farnesyl isoprenoid formation by
these inhibitors could lead to suppression of tumour growth by
interfering with the function of Ras p21. However, there are no
report on whether such inhibitors have potential in cancer patients. 
In this study, we tested whether administration of HMG-CoA
reductase inhibitor would contribute to the survival of patients
with advanced HCC. We administered pravastatin (40 mg day–1),
for which the liver has a high affinity, to HCC patients in a
randomized controlled trial after transcatheter arterial emboliza-
tion (TAE) (Charnsagavej et al, 1983; Yamada et al, 1983;
Stefanini et al, 1995) and oral 5-fluorouracil (5-FU) as standard
treatment. 
PATIENTS AND METHODS 
Patients 
The cohort comprised 91 consecutive patients with unresectable
advanced HCC who were younger than 70 years old (Figure 1); 71
patients were male and 20 were female. The mean age was 62
(ranging from 39 to 70). The diagnosis of cirrhosis was confined
by biochemical data and ultrasonography (US). The histologic
diagnosis of underlying liver disease was carried out in 47 patients
by US-guided liver biopsy. The diagnosis of HCC was based on
clinical features and findings from US, computed tomography, and
hepatic arteriography. Tumour stage (I–IV) was determined
according to the criteria of the Primary Liver Cancer Study Group
of Japan: stage I, a single tumour ≤2 cm in its greatest dimension
without vascular invasion; stage II, a single tumour <2 cm in its
greatest dimension with vascular invasion, or multiple tumours
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with a maximum diameter ≤2 cm confined to one lobe, or a single
tumour with a diameter >2 cm, without vascular invasion; stage
III, a single tumour with a diameter >2 cm, with vascular invasion,
or multiple tumours >2 cm confined to one lobe; stage IV, multiple
tumours in more than one lobe or associated vascular invasion in
the first branch of the portal or hepatic veins (The Liver Cancer
Study Group of Japan, 1989). The histologic diagnosis of HCC
was confirmed in the 47 patients with US-guided biopsy. All
patients had died by the end of February 1998, and the histologic
diagnosis of HCC was confirmed by autopsy or needle necropsy in
all patients. 
As standard treatment, all patients underwent transcatheter
arterial embolization (TAE). For the TAE procedure, patients were
treated with gelatin-sponge particles and ethyl ester of poppyseed
oil fatty acids containing 38% iodine by weight (Lipiodol; Andre-
Gelbe Laboratories, Paris, France) after intraarterial infusion of
doxorubicin (30 mg) (Matsuda et al, 1994). Oral 5-FU at a daily
dose of 200 mg was started 2 weeks after the TAE procedure and
continued for 2 months. 
8 of 91 patients were withdrawn during standard treatment for
any of the following exclusion criteria: hyperbilirubinaemia >51
micro mol l–1; hyperammonaemia >70 micro mol l–1; prothrombin
time >14 seconds; hypoalbuminaemia <25 g l–1; serum alanine
aminotransferase (ALT) level >150 U l–1; or massive ascites. The
remaining 83 patients were randomly divided into control (n = 42)
and pravastatin (n = 41) groups after standard treatment;
randomization was generated by a computer program. Survival
analysis in both groups began on the 15th day after 5-FU was
completed. The pravastatin group received oral drug at a dose of
20 mg beginning on the 15th day after the end of 5-FU administra-
tion. 2 weeks later, pravastatin was increased to 40 mg per day.
The pravastatin group was not treated with any other anti-cancer
drugs. Pravastatin was discontinued when patients showed any of
the exclusion criteria, or signs and symptoms ascribed to adverse
effects of the drug. The control group was not treated with any
anti-cancer drugs. Written informed consent was obtained from all
subjects prior to entry. The protocol in this study was approved by
the local scientific ethical committee. 
Assessment 
Death was the primary endpoint. Clinical status and laboratory
data, including hepatic and renal function tests and haematologic
examinations, were followed at least once a month in the outpa-
tient clinics of Osaka University Hospital and during hospitaliza-
tion. Duing the first 2 months, serum transaminases, bilirubin,
prothrombin time, cholesterol and albumin, were checked weekly
to detect any liver damage due to pravastatin. Serum creatine
kinase activity was also checked every month. Tumour status was
followed by US or computed tomography at least 4 times each
year and tumour marker (AFP, alfa-fetoprotein) monthly. Maximal
diameters of the main tumours in each group were sequentially
measured with US at 2, 6 and 12 months after starting pravastatin
to evaluate its effect on tumour growth. 
Measurement of urinary pravastatin 
Compliance with pravastatin treatment was assessed by detecting
pravastatin in urine according to the method described previously
(Koga et al, 1995). Urine was obtained every 2 months after
entry. 
Statistical analysis 
Fisher’s exact (two-tailed) test was used to compare the baseline
characteristics of both groups. Survival curves were generated by
the Kaplan–Meier method. The log-rank test was used to compare
survival. Factors contributing to survival were selected using the
Cox proportional-hazards regression analysis. Changes in lab-
oratory profiles between the 2 groups were compared using
Mann–Whitney test. 
RESULTS 
91 patients with advanced HCC were enroled between February
1990 and January 1993. All patients underwent TAE and oral
administration of 5-FU. 8 patients were withdrawn because of
progressive liver dysfunction. The control (n = 42) and pravastatin
(n = 41) groups were similar in terms of age, sex, liver function,
renal function, stage of disease (The Liver Cancer Study Group of
Japan, 1989), and presence of vascular invasion in portal veins,
extra-hepatic spread or past history of encephalopathy (Table 1) at
the start of pravastatin treatment. Both groups were not different in
TAE-related complications. 33 patients in the pravastatin group
had cirrhosis versus 34 controls. In the pravastatin group, the
Child–Pugh classification in the cirrhotic patients was class A
for 5 patients and class B for 28, compared with 4 and 30 in the
control group, respectively. The Karnofsky performance scale was
80 to 90 for 34 patients and 60 to 70 for 7 patients in the pravas-
tatin group versus 80 to 90 for 36 patients and 60 to 70 for 6
patients in the control group. HBs Ag was positive in 5 pravastatin
patients and 4 controls. Anti-HCV antibody by second or third
generation ELISA (Ortho Diagnostics, Tokyo) was positive in 33
Eligible patients (n = 91)
Randomization (n = 83)
Pravastatin group (n = 41)
Standard Treatment: TAE and oral
5-FU (n = 91)
Control group (n = 42)
Withdrawal due to advanced liver dysfunction
during or after standard treatment (n = 8)
Pravastatin was stopped
when patients had satisfied
exclusion criteria
Follow-up till death; lost to
follow-up (n = 0)
Follow-up till death; lost to
follow-up (n = 0)
Completed trial (n = 41) Completed trial (n = 42)
Figure 1 Protocol for enrolment, randomization and follow-up. TAE;
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of the pravastatin group and 35 of the control group. Patients were
unresectable because of extensive tumour in 28 pravastatin
patients and 30 controls and because of advanced liver disease in
13 and 12, respectively. The median follow-up was 11 months
(range 2 to 66 months) by the end of February 1998. No patients
were lost to follow-up. 
The duration of pravastatin administration was 16.5 ± 9.8
months (mean ± SD). Pravastatin was discontinued in all patients
because of advancing disease and not because of any adverse
effects of the medicine. The reasons for discontinuation were
hyperbilirubinaemia in 7 patients, prolonged prothrombin time
in 5, massive ascites in 8, hyperammonaemia in 9, and hypoalbu-
minaemia in 12. No patient had an elevation of ALT levels to
>150 U l–1. During the administration period, pravastation was
detected in all urine samples. 
Serum ALT and total bilirubin did not differ between the
2 groups at 2 and 6 months after the start of pravastatin (Table 2).
However, the serum cholesterol concentration was lower in the
pravastatin group at 2 and 6 months (P < 0.001 for both). The
median of total bilirubin level 1 year after entry was 28 micro
mol l–1 (n = 25) in the pravastatin group and 43 (n = 11) in controls
(P = 0.04, Mann–Whitney test). In addition, the median of serum
albumin level 1 year after entry was 31 g l–1 in the pravastatin and
26 in the control group (P = 0.02). These results suggested that
liver function deteriorated more rapidly in the control group. 
By the end of February 1998, all patients in both groups had
died due to HCC progression and/or hepatic failure. The median
survival was 18 months in the pravastatin group and 9 months in
controls. Survival in the pravastatin group was significantly longer
(P = 0.006 by the log-rank test) (Figure 2). Using the Cox
proportional-hazards model, pravastatin was a significant factor
contributing to prolonged survival (P = 0.02 for univariate analysis
and P = 0.005 for multivariate analysis) (Table 3). Absence of the
vascular invasion in portal veins was also a significant factor
contributing to prolonged survival (P = 0.03 for multivariate
analysis). 
Serum AFP level was lower in the pravastatin group compared
with controls 6 months and 1 year after the entry (P = 0.04 and
P = 0.03, respectively; Mann–Whitney test) (Table 2). Regression
of tumour was not observed in the pravastatin group at 2, 6 or 12
months. However, increase in maximal diameter was significantly
less in the pravastatin group at 6 and 12 months compared with
controls (P = 0.03 and P = 0.01, respectively; Mann–Whitney test),
suggesting that tumour growth was suppressed by pravastatin. 
In the control group, 35 patients died of tumour progression and
7 died of hepatic failure. In the pravastatin group, 36 died of
tumour progression and 5 died of hepatic failure. Of the 36 patients
who died of tumour progression in the pravastatin group, 1 had
severe cholestasis due to tumour invasion into the bile ducts, 3 had
massive pleural effusion due to lung metastasis, and 28 had
Table 1 Baseline demographics for pravastatin and control groups 
Variable Pravastatin group (n = 41) Control group (n = 42) P value* 
n (%) n (%) 
Age (y) 
<60 15 (37) 19 (45) >0.2 
³60 26 (63) 23 (55) 
Sex 
Female 10 (24) 8 (20) >0.2 
Male 31 (76) 34 (80) 
Tumour stage 
IV 11 (27) 13 (31) >0.2 
II or III 30 (73) 29 (69) 
Vascular invasion in portal veins 
Yes 5 (12) 6 (14) >0.2 
No 36 (88) 36 (86) 
Extra-hepatic spread 
Yes 2 (5) 1 (2) >0.2 
No 39 (95) 41 (98) 
Serum ALT** level 
<60 U l–1 25 (61) 23 (55) >0.2 
³60 U l–1 16 (39) 19 (45) 
Serum alkaline phosphatase level 
<200 IU l–1 26 (63) 24 (57) >0.2 
³200 IU l–1 15 (37) 18 (43) 
Serum albumin level 
³35 g l–1 21 (51) 20 (47) >0.2 
<35 g l–1 20 (49) 22 (53) 
Serum total bilirubin level 
<22 micro mol l–1 17 (41) 19 (45) >0.2 
³22 micro mol l–1 24 (59) 23 (55) 
Serum creatinine level 
<1.2 mg dl-1 21 (51) 20 (47) >0.2 
³1.2 mg dl-1 20 (49) 22 (53) 
Past history of encephalopathy 
Yes 2 (5) 2 (5) >0.2 
No 39 (95) 40 (95) 
Tumour stage was according to the criteria of the Liver Cancer Study Group of Japan (The Liver Cancer Study
Group of Japan, 1989). *Fisher’s exact test; **alanine aminotransferase. Effect of pravastatin on human hepatoma 889
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massive ascites due to the obstruction of the portal vein by tumour.
Of the 5 patients who died of hepatic failure in the pravastatin
group, 3 patients developed hepatic coma with progressive
cirrhosis, and 2 had rupture of gastric varices. 
DISCUSSION 
Chemotherapy that prolongs survival is not available for advanced
HCC. To test whether pravastatin, a potent HMG-CoA reductase
inhibitor, might increase the survival of patients with advanced
HCC, we designed a randomized clinical trial with death as the
primary endpoint. We chose TAE and 5-FU as standard treatment
before introducing pravastatin administration. TAE prevents
tumour progression (Charnsagavej et al, 1983; Yamada et al, 1983;
Stefanini et al, 1995) and is one of the standard treatments for
unresectable HCC in Japan. 5-FU also has activity against HCC
(Cavalli et al, 1981; Coi et al, 1984; Falkson et al, 1984). To avoid
any bias based on pretreatment, all 91 patients underwent a single
TAE followed by oral 5-FU at a uniform dose for 2 months.
83 patients completed the standard treatment and were randomly
assigned to pravastatin or control groups. 
Patients in the pravastatin group survived significantly longer
than those in the control group (Figure 2). Analysis using the Cox
proportional-hazards model showed that treatment with pravas-
tatin was the significant factor contributing to prolonged survival
(P = 0.02 for univariate analysis and P = 0.005 for multivariate
analysis). This result suggests that HMG-CoA reductase inhibitors
offer a survival advantage in the treatment of advanced HCC. 
The biochemical data after randomization suggested that liver
function deteriorated more rapid in patients who were not taking
pravastatin (Table 2). This may represent more rapid progression
of either tumour or underlying liver disease in the control groups.
Serum AFP concentrations more rapidly increased in controls
(Table 2). Regression of the main tumour was not observed in the
pravastatin group. Yet, growth of the main tumours was signifi-
cantly slowed at 6 and 12 months after pravastatin administration,
suggesting that pravastatin suppressed tumour growth. Pravastatin
effects on survival may therefore have resulted from stabilization
Table 2 Changes in liver function test and tumour markers after start of pravastatin administration 
Variable Pravastatin group (n = 41) Control group (n = 42) P value 
Serum ALT* level (U l–1) 
Baseline 58# (42–85)## 63 (45–97) > 0.2 
2M 57 (39–90) (n = 41) 65 (42–92) (n = 42) > 0.2 
6M 60 (40–86) (n = 35) 59 (43–108) (n = 22) > 0.2 
1Y 52 (36–74) (n = 25) 68 (48–93) (n = 11) > 0.2 
Serum total bilirubin level (micro mol l–1) 
Baseline 24 (18–37) 25 (18–40) > 0.2 
2M 25 (19–35) (n = 41) 28 (19–44) (n = 42) > 0.2 
6M 28 (21–38) (n = 35) 36 (25–55) (n = 22) > 0.2 
1Y 28 (22–40) (n = 25) 43 (24–58) (n = 11) 0.04 
Serum albumin level (g l–1) 
Baseline 35 (29–40) 36 (26–38) > 0.2 
2M 36 (28–41) (n = 41) 34 (25–36) (n = 42) > 0.2 
6M 33 (26–37) (n = 35) 29 (24–34) (n = 22) 0.06 
1Y 31 (24–35) (n = 25) 26 (23–32) (n = 11) 0.02 
Serum AFP level (ng dl–1) 
Baseline 130 (25–5140) 120 (5–3450) > 0.2 
2M 108 (21–4270) (n = 41) 172 (45–6710) (n = 42) > 0.2 
6M 218 (60–6540) (n = 35) 292 (85–9573) (n = 22) 0.04 
1Y 261 (78–7940) (n = 25) 4140 (140–17300) (n = 11) 0.03 
Serum total cholesterol level (mmol l–1) 
Baseline 4.30 (3.67–5.03) 4.20 (3.58–4.96) > 0.2 
2M 3.56 (3.25–3.94) (n = 41) 3.93 (3.42–4.75) (n = 42) < 0.001 
6M 3.24 (2.80–3.82) (n = 35) 3.78 (3.52–4.63) (n = 22) < 0.001 
1Y 3.10 (2.63–3.55) (n = 25) 3.40 (2.86–4.07) (n = 11) 0.03 
Diameter of main tumour (mm) 
Baseline 38 (22–48) 36 (24–52) > 0.2 
2M 40 (24–52) (n = 41) 43 (25–62) (n = 42) > 0.2 
6M 45 (30–67) (n = 35) 60 (34–83) (n = 22) 0.03 
1Y 52 (42–78) (n = 25) 73 (45–106) (n = 11) 0.01 
2M, 2 months after pravastatin; 6M, 6 months after pravastatin; 1Y, 1 year after pravastatin. # Median of values,
## range of values. 
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Figure 2 Kaplan–Meier survival curves in pravastatin (n = 41) and control
(n = 42) groups. The median survival was 18 months in the pravastatin group
and 9 months in the control group (P = 0.006 by the log-rank test) 890 S Kawata et al 
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of the tumour. Signal transduction inhibitors are generally cyto-
static in their activity against malignant cells, and our results are
consistent with other in vivo studies (Stebolt-Leopold et al, 1999). 
Long-term administration of a daily dosage of 40 mg of pravas-
tatin has been reported to prevent cardiovascular events (Byington
et al, 1995; Shepherd et al, 1995). This dosage was well-tolerated
without severe adverse effects. Because our patients had advanced
HCC with chronic hepatitis and/or cirrhosis, we administered a
daily dose of 20 mg of pravastatin during the first 2 weeks to check
adverse effects. No significant problems were noted, and all
patients subsequently received 40 mg of pravastatin. During
the first 2 months, we found no elevations of serum bilirubin or
transaminase values which could be attributed to pravastatin.
Throughout the observation period, there were no significant
differences in liver function tests or haematologic data between the
2 groups. After 2 months, pravastatin was continued until exclu-
sion criteria were satisfied. All patients in the pravastatin group
appeared to die of progressive disease. 
Patients with chronic liver disease often have muscle cramps. In
this study, the frequency of muscle cramps did not differ between
the 2 groups (data not shown). None of the patients in either group
showed more than a 10-fold elevation in serum creatine kinase
values. In general, patients with advanced HCC tolerated long-
term administration of a daily dose of 40 mg of pravastatin. 
HMG-CoA reductase inhibitors have been reported to have cyto-
static activity, possibly due to suppression of protein isoprenylation
(Sinensky et al, 1990). Cholesterol is a primary source for
membrane formation and thus is in great demand in rapid-growth
tissues such as cancers. Previously, we reported that HMG-CoA
reductase activity and protein content, as well as cholesterol bio-
synthesis, were increased in human HCC tissues (Kawata et al,
1990). The liver has a high affinity for pravastatin (Tsujita et al,
1986). Prior to this study, we observed that pravastatin at a daily
dose of 40 mg led to a significant decrease in serum concentrations
of cholesterol and AFP in 3 patients with hypercholesterolaemia
associated with HCC as a paraneoplastic syndrome (data not
shown). This agent might have been effectively taken up to
hepatoma cells in vivo. In future studies, to clarify the mechanism(s)
whereby pravastatin may prolong survival in advanced HCC, liver
biopsy should be done before and after therapy to monitor changes
in protein isoprenylation and cholesterol content in tumour cells. 
This study was not blinded, although it was randomized. The
study also included treatment with TAE and oral 5-FU, although
randomization was done after completion of those treatments.
Table 3 Factors contributing to survival in HCC patients 
Univariate analysis Multivariate analysis 
Variable Risk ratio 95% CI* P value# Risk ratio 95% CI P value 
Age 
< 60 1 1 
³ 60 1.72 0.58–4.84 >0.2 1.30 0.67–2.65 >0.2 
Sex 
Female 1 1 
Male 0.62 0.22–1.72 >0.2 0.82 0.38–1.70 >0.2 
Tumour stage 
IV 1 1 
II or III 0.67 0.22–2.06 >0.2 0.72 0.34–1.63 >0.2 
Vascular invasion in portal veins 
Yes 1 1 
No 0.38 0.12–1.25 0.10 0.18 0.04–0.81 0.03 
Extra-hepatic spread 
Yes 1 1 
No 0.65 0.22–1.98 >0.2 0.57 0.25–1.62 >0.2 
Serum ALT## level 
<60 U l–1 11  
³60 U l–1 1.46 0.45–4.64 >0.2 1.80 0.85–4.16 >0.2 
Serum alkaline phosphatase level 
<200 IU l–1 11  
³200 IU l–1 2.05 0.66–6.35 >0.2 1.47 0.64–3.67 >0.2 
Serum albumin level 
³35 g l–1 11  
<35 g l–1 1.33 0.43–4.35 >0.2 1.58 0.68–3.15 >0.2 
Serum total bilirubin level 
<22 micro mol l–1 11  
>22 micro mol l–1 2.3 0.71–7.46 >0.2 1.35 0.62–3.05 >0.2 
Serum creatinine level 
<1.2 mg dl–1 11  
³1.2 mg dl–1 1.84 0.56–6.13 >0.2 1.63 0.55–4.65 >0.2 
Past history of encephalopathy 
Yes 1 1 
No 0.67 0.21–2.08 >0.2 0.52 0.18–1.50 >0.2 
Pravastatin administration 
No 1 1 
Yes 0.42 0.20–0.83 0.02 0.35 0.17–0.61 0.005 
*CI denotes confidence interval. # Cox proportional-hazards regression analysis. ## analine aminotransferase. Effect of pravastatin on human hepatoma 891
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These factors may have introduced bias in assessing the effect of
pravastatin on survival. In the future, a randomized, placebo-
controlled, double-blind study will be needed to clarify whether
HMG-CoA reductase inhibitors are useful as adjuvant anti-cancer
therapy. 
In conclusion, pravastatin prolonged the survival of patients
with advanced HCC. This result should encourage the develop-
ment of HMG-CoA reductase inhibitors as adjuvant therapy
against HCC. 
ACKNOWLEDGEMENTS
This work was supported in part by a Grant-in-Aid for Cancer
Research to S Kawata (Grant No. 07274240) from the Ministry of
Education, Science, and Culture in Japan. 
REFERENCES 
Byington KP, Jukema JW, Salonen JT, Bertram P, Bruscheke AV, Hoen H, 
Furberg CD and Mancini GBJ (1995) Reduction in cardiovascular events
during pravastatin therapy. Pooled analysis of clinical events of the pravastatin
atherosclerosis intervention program. Circulation 92: 2419–2425 
Cavalli F, Rozencweig M, Goldhirsch A and Hansen HH (1981) Phase II study of
oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17:
1079–1082 
Charnsagavej S, Chuang VP, Wallace S, Soo CS and Bowers T (1983) Transcatheter
management of promary carcinoma of the liver. Radiology 147: 51–55 
Coi TK, Lee NW and Wong J (1984) Chemotherapy for advanced hepatocellular
carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53: 401 
Di Bisceglie AM (1995) Hepatitis C and hepatoecllular carcinoma. Seminar Liver
Dis 15: 64–69 
El-Serag HB and Mason AC (1999) Rising incidence of heptocellular carcinoma in
the United States. N Engl J Med 340: 745–750 
Falkson G, MacIntyre JM, Moertel CG, Johnson LA and Scherman RC (1984)
Primary liver cancer: An Eastern JM Cooperative Oncology Group Trial.
Cancer 54: 970–977 
Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, 
Scolnick EM, Kohl NE and Oliff A (1993) Selective inhibition of farnesyl:
transferase blocks ras processing in vivo. J Biol Chem 268: 7617–7620 
Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. 
Nature 343: 425–430 
Goldstein JL, Helgeson JAS and Brown MS (1979) Inhibition of cholesterol
synthesis with compactin renders growth of cultured cells dependent on the low
density lipoprotein receptors. J Biol Chem 254: 5403–5409 
Habenicht AJR, Glomset JA and Ross R (1980) Relation of cholesterol and
mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells
stimulated to divide by platelet-derived growth factor. J Biol Chem 255:
5134–5140 
James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS,
Crowley CW, Lucas BK, Levinson AD and Marsters Jr JC (1993)
Benzodiazepine peptidomimetics: protein inhibitor of ras farnesylation in
animal cells. Science 260: 1937–1942 
Kandutsch AA and Chen HW (1979) Consequences of blocked sterol synthesis in
cultured cells, DNA synthesis and membrane composition. J Biol Chem 252:
409–415 
Kawata S, Takaishi K, Nagase T, Ito N, Tamura S, Matsuzawa Y and Tarui S (1990)
Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A
reductase in human hepatocellular carcinoma: Possible mechanism for
alteration of cholesterol biosynthesis. Cancer Res 50: 3270–3273 
Koga T, Kawabata K, Arai K, Matsushima N, Koike H, Komai T, Rei M and
Nakamura H (1995) Comparative pharmacokinetics of pravastatin and
simvastatin. Bull Mol Biol Med 20: 103–105 
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith
RL, Scolnick EM, Oliff A and Gibbs JB (1993) Selective inhibition of
ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:
1934–1937 
Maltese WA, Defendini R, Green RA, Sheridan KM and Donley DK (1985)
Suppression of murine neuroblastoma growth in vivo by mevinolin, a
competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. 
J Clin Invest 76: 1748–1754 
Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, Ishiguro H and
Matsuzawa Y (1994) Interleukin-6 in transcatheter arterial embolization for
patients with hepatocellular carcinoma. Cancer 73: 53–57 
Okuda K (1992) Hepatocellular carcinoma: recent progress. Hepatology 15:
948–963 
Okuda K, Fujimoto I, Hanai A and Urano Y (1987) Changing incidence of
hepatocellular carcinoma in Japan. Cancer Res 47: 4967–4972 
Shepherd J, Lobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, 
Mackillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study
Group (1995) Prevention of coronary heart disease with pravastatin in men
with hypercholesterolemia. N Engl J Med 333: 1301–1307 
Simonetti RG, Camma C, Fiorello F, Politi F, D’amico G and Pagliaro L (1991)
Hepatocellular carcinoma. A worldwide problem and the major risk factors.
Dig Dis Sci 36: 962–972 
Sinensky M, Beck LA, Leonard S and Evans R (1990) Differential inhibitory effects
of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265:
19937–19941 
Stebolt-Leopold JS, Dudley DT, Herrera R, Becelaere KV, Wiland A, Gowan RC,
Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR
(1999) Blockade of the MAP kinase pathway suppresses growth of colon
tumors in vivo. Nature Med 5: 810–816 
Stefanini GF, Amorati P, Beselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C,
Re G and Gasbarrini G (1995) Efficacy of transarterial targeted treatment on
survival of patients with hepatocellular carcinoma. Cancer 75: 2427–2434 
The Liver Cancer Study Group of Japan (1989) The general rules of the clinical and
pathological study of primary liver cancer. Jpn J Sur 19: 98–129 
Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M,
Matsuda H, Tarumi C, Watanabe Y and Fujii S (1986) CS-514, a competitive
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-
selective inhibiton of sterol synthesis and hypolipidemic effect on various
animal species. Biophys Biochem Acta 877: 50–60 
Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S
(1983) Hepatic artery embolization in 120 patients with unresectable hepatoma.
Radiology 148: 397–401
APPENDIX 
Current author addresses 
Dr Kawata: Second Department of Internal Medicine, Yamagata
University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 
990-9585, Japan. 
Drs Yamasaki, Nagase, Inui, Ito, Tamura, and Matsuzawa:
Department of Internal Medicine and Molecular Science,
Graduate School of Medicine, B5, Osaka University, 2-2 Yamada-
oka, Suita, Osaka 565-0871, Japan. 
Drs Matsuda and Inada: Department of Internal Medicine,
Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka,
Osaka 5675, Japan. 
Dr Noda: Department of Internal Medicine, Suita Municipal
Hospital, 2-13-20 Katayama-cho, Suita, Osaka 564, Japan. 
Dr. Imai: Department of Internal Medicine, Ikeda Municipal
Hospital, 3-1-18 Johnan, Ikeda, Osaka 563; Japan. 